We will focus on hormonally driven cancer, such as breast and endometrial cancers, and on the changes in peptide and steroid hormones, including insulin and insulin-like growth factors (IGFs), various adipokines such as leptin and adiponectin, and oestrogen, that link metabolic dysfunction with chronic low-level systemic inflammation. This evidence concerns the gene INS and cancer.